Centrus Energy Corp

Thesis

Centrus is the only U.S.-owned uranium enricher and the only NRC-licensed HALEU producer, with a $3.9B backlog extending to 2040 and a signed $900M DOE task order that converts its Piketon cascade from demonstration to commercial operation — over five years its revenue should roughly triple as HALEU production and expanded LEU capacity come online. At $170.78 (~6x TTM sales), however, the market already pays for most of that build-out: our defensible base case yields only ~6%/yr and a probability-weighted PV of ~0.77x price, so this publishes as a watchlist thesis with an entry zone near $100-110, not a buy at today's price. The operating thesis is falsified if backlog drops below $3.5B for two consecutive quarters, cumulative DOE obligations under the $900M task order stall below $300M by the FY2027 10-K, or TENEX deliveries halt without offsetting domestic volume.

Why Now

The inflection is contractual, not narrative, and it is dated to the last eight months of filings. The FY2025 10-K (filed 2026-02-11) reported revenue of $448.7M (LEU segment $346.2M, Technical Solutions $102.5M) and net income of $77.8M ($3.90 diluted), and disclosed DOE's selection of Centrus for a $900.0M HALEU production award. The Q1 2026 10-Q (period ended 2026-03-31, filed 2026-05-06) then showed the order book that award anchors: total backlog of $3.9B extending to 2040 — $3.1B in the LEU segment (including $2.4B of contingent sales contracts, all under definitive agreements, tied to construction of new LEU capacity at Piketon) and $0.8B in Technical Solutions. Q1 revenue was $76.7M versus $73.1M a year earlier (Q1 2025 10-Q, filed 2025-05-08), and management raised 2026 revenue guidance to $450-500M from $425-475M while guiding $350-500M of capital deployment — the clearest signal yet that the expansion is moving from optionality to construction.

The decisive event came after quarter-end: on June 30, 2026, Centrus's subsidiary American Centrifuge Operating signed the $900M DOE task order (competitively awarded in January 2026 as part of DOE's ~$2.7B enrichment awards), which both funds HALEU expansion and clears the Piketon cascade to transition from government-funded demonstration to commercial operation. Centrus completed the final 900 kg deliverable under the demonstration contract in mid-June 2026, bringing cumulative HALEU output above 1,900 kg — it remains the only entity that has actually produced HALEU at scale on U.S. soil with U.S. technology. In parallel, the company announced a $560M centrifuge-manufacturing expansion at Oak Ridge with Fluor and Palantir.

The balance sheet was pre-funded into 2025's nuclear-equity froth: cash and equivalents of $1,868.2M against $1,176.1M of long-term debt at March 31, 2026 (Q1 2026 10-Q) — roughly $690M of net cash — after convertible raises took long-term debt from $390M (June 2025) to $1,173.5M (Q3 2025 10-Q, filed 2025-11-06) and diluted weighted-average shares from 16.4M (FY2024 10-K) to 22.4M (Q1 2026 10-Q). That financing is why the expansion is credible; it is also why the stock is no longer cheap on a per-share basis. Finally, the regulatory clock is the forcing function: the Prohibiting Russian Uranium Imports Act bans Russian LEU through 2040, and Centrus's DOE waiver covers only committed deliveries through 2027 — every year that passes converts Centrus's Russian-supplied legacy book into a build-or-die case for the domestic capacity its $2.4B contingent backlog is contracted against.

Business Quality

The moat is licensure and incumbency in a market where entry takes a decade. Centrus is the only U.S.-owned, U.S.-technology enricher (Urenco USA and Orano's planned plant are European-owned, which matters for defense-adjacent and HALEU-for-government work), and it holds the only NRC license for HALEU production — with more than 1,900 kg actually produced, versus zero for every would-be competitor. The $3.9B backlog to 2040 embeds long-dated utility relationships, and the $2.4B contingent tranche is under definitive agreements — customers have already signed for output from capacity that doesn't exist yet, which is as strong a demand signal as this industry produces. Enrichment at scale is a superb business: Urenco, the mature comp, runs ~50% EBITDA margins on take-or-pay contracts.

Today's unit economics are more modest than the endgame. FY2025 gross margin was ~26% ($117.5M on $448.7M), because the LEU segment largely resells Russian (TENEX) and other purchased SWU rather than self-produced material, and Technical Solutions is substantially cost-reimbursable government work. The bridge from 26%-gross-margin reseller to Urenco-like producer economics runs straight through a multi-billion-dollar, multi-year centrifuge build — nuclear construction, with all the schedule risk that implies. Q1 2026 already shows the shape of the transition: net income fell to $10.0M from $27.2M on higher advanced-technology spend even as revenue grew.

Capital allocation has been opportunistic and, so far, shrewd: management sold equity and convertibles aggressively into the 2025 run-up (the stock touched $464 in late 2025), banking $1.87B of cash before the froth unwound — dilution of ~37% in diluted share count over five quarters was real, but it pre-funded the first expansion phases and the $900M task order shifts a large slice of HALEU capex onto the government. Competition is arriving — DOE deliberately split ~$2.7B across multiple awardees, Urenco is expanding Eunice, and Orano has announced a U.S. plant — but the constraint on all of them is the same licensing-and-construction decade Centrus has already spent. The realistic risk is not displacement; it is that Centrus builds slower and more expensively than the contracts assume, while the resale book that funds the interim shrinks under the Russian import ban.

Financial Base

Reference figures as of 2026-07-23: trailing-twelve-month revenue of $452M, 22.4M diluted shares, net debt of $-689M, and a share price of $170.78. Sources:

• 10-Q Q1 FY2026 (period 2026-03-31), filed 2026-05-06 — Q1 revenue $76.7M; cash & equivalents $1,868.2M; long-term debt $1,176.1M; diluted weighted-average shares 22,446,000; backlog $3.9B to 2040 ($3.1B LEU incl. $2.4B contingent, $0.8B Technical Solutions)
• 10-K FY2025, filed 2026-02-11 — FY2025 revenue $448.7M (LEU $346.2M, Technical Solutions $102.5M); net income $77.8M; diluted EPS $3.90; DOE selection for $900M HALEU award
• 10-Q Q1 FY2025, filed 2025-05-08 — Q1 2025 revenue $73.1M (TTM bridge: $448.7M − $73.1M + $76.7M = $452.3M)
• 10-Q Q3 FY2025, filed 2025-11-06 — long-term debt $1,173.5M at 2025-09-30 (post-convertible raise), cash $1,631.8M
• Company press release 2026-06-30 (8-K) — $900M DOE task order signed by American Centrifuge Operating; cumulative HALEU production >1,900 kg; Piketon cascade transitioning to commercial operation
• Share price $170.78 at 2026-07-23 close per stockanalysis.com (market cap $3.36B on 19.67M shares outstanding); net debt = $1,179.0M total debt − $1,868.2M cash = −$689.2M

Scenario Valuation

Five-year scenario ranges under the published methodology — the tables below are computed from these exact parameters at publication and sealed with this text. What each scenario assumes:

• Loss (10%): DOE appropriations for the task order are curtailed and the Piketon LEU expansion never reaches FID, while TENEX supply is severed (Russian export-license denial or waiver lapse post-2027) before domestic capacity replaces it; the $2.4B contingent backlog lapses and the company burns build capital against a shrinking resale book, reverting toward net cash plus a legacy contracting business.
• Bear (25%): Advanced-reactor (SMR) deployment slips years, HALEU demand beyond the government program fails to materialize, and the LEU capacity expansion is shelved; revenue compounds only ~8%/yr on Technical Solutions and the existing book, and the market re-rates Centrus to a no-growth government contractor at ~3x EV/sales (low end of BWXT's historical 3-5x range).
• Base (45%): The $900M task order executes on schedule, the Oak Ridge manufacturing expansion delivers centrifuges, and the first Piketon LEU expansion phase reaches FID by 2027 and first revenue ~2030, lifting revenue to ~$1.2B by mid-2031 (22%/yr); exit at 4.5x EV/sales, mid-range of mature government-nuclear comps (BWXT historical 3-5x, Cameco pre-froth 4-6x), justified by Urenco-like margin potential not yet proven.
• Bull (20%): Full national-champion outcome: the $2.4B contingent backlog converts to firm as multiple Piketon phases are funded (further DOE awards plus allied-government offtake), HALEU commercial demand arrives with the first operating SMRs, and revenue reaches ~$1.8B by 2031 (32%/yr); exit at 6x EV/sales, a strategic-asset premium defensible only if Urenco-like ~50% EBITDA margins are demonstrated.

Published range (present value): $50.00 – $239.06 · probability-weighted expected value $132.15 against $170.78 at drafting (0.77×) · base-case IRR +5.8%/yr. Gates: base IRR ≥ 15% and EV ≥ 1.3× — both passed at publication. Ranges are graded at the 1-year checkpoint and the 5-year horizon. This is a range, not a target.

Sensitivity — present value across growth × exit multiple

The shaded cell is the one today's price of $170.78 most closely implies. Find your own cell — we show our work rather than assert a number.

Kill Conditions

1. 1. Total backlog falls below $3.5B for two consecutive quarterly 10-Qs (from $3.9B at Q1 2026) — contingent contracts lapsing rather than converting to firm.
2. 2. Cumulative DOE obligations/funding disclosed under the $900M HALEU task order fail to reach $300M by the FY2027 10-K, or the task order is descoped or terminated.
3. 3. TENEX deliveries halt (Russian export-license denial or U.S. waiver lapse for 2027+) AND LEU segment revenue declines >25% year-over-year for two consecutive quarters without offsetting domestic production revenue.
4. 4. No final investment decision announced on the Piketon LEU capacity expansion by the FY2027 10-K (Feb 2028) while the $2.4B contingent LEU backlog shrinks sequentially for two quarters.
5. 5. Cash and equivalents fall below $750M in any 10-Q before first revenue from expanded LEU capacity, without a matching increase in property, plant & equipment (burn not converting into productive assets).

Risk Register

• Russian supply dependence — HIGH: TENEX remains Centrus's largest LEU supplier under the 2011 contract; the DOE waiver covers only committed deliveries through 2027, Russia has already imposed shipment-by-shipment export licensing, and the LEU segment was $346.2M (77%) of FY2025 revenue.
• Nuclear construction execution — HIGH: the base case requires a first-of-a-kind-scale centrifuge plant to reach revenue by ~2030; the industry's base rate for on-time, on-budget nuclear construction is poor.
• Valuation / multiple compression — HIGH: at $170.78 the stock trades ~60x TTM earnings and ~6x TTM sales, already 63% off its October 2025 high of $464; the 2025 nuclear froth unwind is incomplete.
• Government dependence — MEDIUM-HIGH: the $900M task order and much of Technical Solutions are subject to annual appropriations and DOE program continuity.
• HALEU demand timing — MEDIUM-HIGH: no advanced reactor that burns HALEU is yet in commercial operation; if TerraPower/X-energy/Oklo timelines slip, commercial HALEU demand slips with them.
• Dilution — MEDIUM: diluted weighted-average shares grew ~37% in five quarters (16.4M FY2024 to 22.4M Q1 2026); a multi-phase build likely requires more equity than our 4%/yr base assumption.
• Emerging competition — MEDIUM: DOE split ~$2.7B across multiple enrichment awardees; Urenco USA is expanding Eunice and Orano has announced a U.S. plant, capping long-run pricing.
• Legacy liabilities — LOW-MEDIUM: pension and decommissioning-era obligations from the USEC inheritance remain on the balance sheet.

Theme Position

Revenue exposure to the nuclear-fuel-cycle theme is effectively 100%: the LEU segment ($346.2M, 77% of FY2025 revenue) sells enriched uranium and SWU to utilities, and Technical Solutions ($102.5M, 23%) is fuel-cycle engineering and the HALEU demonstration/production work itself. No other listed company offers pure-play exposure to U.S. enrichment — the single most supply-constrained link in the Western fuel cycle.

Alternatives considered: Cameco (CCJ) — the highest-quality diversified play (mining + Westinghouse), but it is a ~$25B+ company whose enrichment exposure is nil and whose theme upside is spread across links that are not supply-constrained; it dilutes the specific angle. BWXT — mature, superbly run government nuclear franchise, but it makes reactor components and naval fuel, not commercial enrichment; it is the comp for our exit multiple, not the vehicle for the thesis. Oklo / ASP Isotopes / General Matter / Silex-GLE — the HALEU-adjacent field is either pre-revenue, private, or carrying unproven technology risk (laser enrichment); none has an NRC production license or a kilogram of output. Urenco and Orano, the incumbent enrichers, are unlisted. Centrus is the only investable security whose equity value is a direct function of whether America rebuilds domestic enrichment — which is precisely the theme.

Benchmark

Beating means LEU total return exceeds QQQ total return over the full 5-year window from publication date (2026-07-24). Success means beating QQQ's total window return from publication; the scoreboard grades this thesis against that bar, live, whether we like the answer or not.